1035219-80-7

Usage

Uses

Used in Medicinal Chemistry:
2-Bromothiazolo[5,4-c]pyridin-4(5H)-one is utilized as a compound of interest in medicinal chemistry for its potential to display biological activity. Its unique structure, which includes a thiazole-pyridine fusion and a bromine atom, suggests that it may interact with biological targets in ways that could be harnessed for therapeutic purposes.
Used in Drug Discovery and Development:
In the pharmaceutical industry, 2-Bromothiazolo[5,4-c]pyridin-4(5H)-one is used as a starting material or a scaffold in the design and synthesis of new drugs. Its chemical properties and structural features make it a candidate for further modification and optimization to develop potential therapeutic agents.
Used in Chemical Research:
2-Bromothiazolo[5,4-c]pyridin-4(5H)-one serves as a subject of study in chemical research, where scientists investigate its reactivity, stability, and the possibility of forming derivatives. Understanding these aspects can lead to the discovery of new chemical reactions or the creation of novel compounds with specific applications.

Upstream product

• 108-05-4 vinyl acetate 
• 1035219-79-4 3-(2-bromothiazol-4-yl)acrylic acid 

Downstream Products

• 1035219-81-8 2-(4-cyclopropoxyphenyl)-5H-thiazolo[5,4-c]pyridin-4-one 

Relevant academic research and scientific papers

ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF

The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

5- [4- (AZETIDIN-3-YL0XY) -PHENYL] -2-PHENYL-5H-THIAZ0L0 [5,4-C] PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein "-----" is absent or is optionally a bond; q is 1 or 2; R1 is independently selected from hydrogen, -C1-C2 alkyl, halo, hydroxy, -C1-C2 haloalkyl, -C1-C3 alkoxy, cyano, -O-C3-C4 cycloalkyl, and -OC1-C2 haloalkyl; R2 is selected from the group consisting of hydrogen, -C1-C3 alkyl, hydroxy, -C1-C3 alkoxy, cyano, -C1-C2 haloalkyl, -OC1-C2 haloalkyl, and halo; R3 is selected from the group consisting of hydrogen, -C1-C4 alkyl, -C2-C4 haloalkyl, -C2-C4 alkylOH, -C3-C6 cycloalkyl, -CH2C3-C6 cyxloalkyl, -C2-C4 alkyl-O-C1-C4 alkyl, -C(O)C1-C4 alkyl, -C(O)C1-C4 haloalkyl, -CH2-thiazole, phenyl, benzyl, tetrahydrothiopyranyl, and tetrahydropyranyl, wherein the cycloalkyl, tetrahydrothiopyranyl, tetrahydropyranyl and thiazolyl group is optionally substituted with one or two groups independently selected from the group consisting of halo, hydroxy, C1-C2 alkyl, and -C1-C2 haloalkyl; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof,, useful in the treating, preventing or ameliorating of symptoms associated with obesity and related diseases.